サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：淋病診断薬市場- 成長、将来展望、競争分析、2023年～2031年
市場調査レポート
商品コード
1255993

淋病診断薬市場- 成長、将来展望、競争分析、2023年～2031年

Gonorrhea Diagnostics Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日: | 発行: Acute Market Reports | ページ情報: 英文 119 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
淋病診断薬市場- 成長、将来展望、競争分析、2023年～2031年
出版日: 2023年01月30日
発行: Acute Market Reports
ページ情報: 英文 119 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

淋病は、膣、肛門、尿道、喉、目など、体内の湿った温かい場所に感染する淋菌の感染によって引き起こされます。淋病は、無防備なセックスや複数のセックスパートナーを持つことによって感染する危険性があるため、性感染症（STD）の中でも2番目に多く発生する病気とされています。罹患率が高く、セファロスポリンに耐性を持つ淋病の脅威が高いため、淋病の疫学を理解することが必要です。米国疾病対策センター（Centers for Disease Control and Prevention）の2016年報告書を引用した最新の調査によると、淋病の世界有病率は10万人あたり142.1件です。男性に比べて女性の発生率が高く、北米、ラテンアメリカ、アフリカ、南アジアの発展途上国などの地域で広く流行しています。

世界保健機関は、微生物耐性の問題を克服するために、淋病の治療ガイドラインを策定し、第三世代セファロスポリン、ドキシサイクリン、アジスロマイシン、ゲミフロキサシンなどの抗生物質を使用することを決定しています。淋病の効果的な診断には、高い特異性、高い感度、比較的安価であるなどの特徴から、細胞培養標準検査がゴールドスタンダードと考えられています。しかし、ナイセリア菌の細胞培養には、保存や輸送中に菌の生存率を維持する必要があり、予備培養の結果が得られるまでに約24～72時間を要するという問題があります。核酸増幅検査（NAAT）は、性器検体のみを分析するためにUSFDAによって承認されており、非常に少ない遺伝物質、尿サンプルおよび膣スワブで陽性結果を得るのに有益です。性器外検体の分析には、血清学的検査、モノクローナル抗体検査、フローサイトメトリーなどを用いて淋病の診断が行われています。

目次

第1章 序文

  • レポート内容
    • 報告書の目的
    • 対象読者
    • 主な提供商品
  • 市場セグメンテーション
  • 調査手法
    • フェーズI-二次調査
    • フェーズII-一次調査
    • フェーズIII-有識者別レビュー
    • 前提条件
    • 採用したアプローチ

第2章 エグゼクティブサマリー

  • 市場のスナップショット：世界の淋病診断薬市場
  • 世界の淋病診断薬市場：タイプ別 2022
  • 世界の淋病診断薬市場：地域別 2022
  • 魅力的な投資提案：地域別 2022

第3章 淋病診断薬市場：競合分析

  • 主要ベンダーの市場ポジショニング
  • ベンダーが採用する戦略
  • 主要な産業戦略
  • ティア分析：2022 vs. 2031

第4章 淋病診断薬市場：マクロ分析と市場力学

  • イントロダクション
  • 世界の淋病診断薬市場金額 2021-2031
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析

第5章 淋病診断薬市場：タイプ別 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs. 2031
  • 市場セグメンテーション
    • フローサイトメトリー
    • 画像診断
    • ゲル微小液滴
    • クロマトグラフィー
    • リポソーム
    • モノクローナル抗体検査
    • 微分光散乱
    • 分子診断検査
      • スワブテスト
      • 核酸増幅試験（NAAT）

第6章 北米の淋病診断薬市場 2021-2031

  • 市場概要
  • 淋病診断薬市場：タイプ別 2021-2031
  • 淋病診断薬市場：地域別 2021-2031
    • 北米
      • 米国
      • カナダ
      • その他北米地域

第7章 英国と欧州連合淋病診断薬市場 2021-2031

  • 市場概要
  • 淋病診断薬市場：タイプ別 2021-2031
  • 淋病診断薬市場：地域別 2021-2031
    • 英国と欧州連合
      • 英国
      • ドイツ
      • スペイン
      • イタリア
      • フランス
      • その他欧州地域

第8章 アジア太平洋の淋病診断薬市場 2021-2031

  • 市場概要
  • 淋病診断薬市場：タイプ別 2021-2031
  • 淋病診断薬市場：地域別 2021-2031
    • アジア太平洋
      • 中国
      • 日本
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域

第9章 ラテンアメリカの淋病診断薬市場 2021-2031

  • 市場概要
  • 淋病診断薬市場：タイプ別 2021-2031
  • 淋病診断薬市場：地域別 2021-2031
    • ラテンアメリカ
      • ブラジル
      • メキシコ
      • その他ラテンアメリカ地域

第10章 中東・アフリカの淋病診断薬市場 2021-2031

  • 市場概要
  • 淋病診断薬市場：タイプ別 2021-2031
  • 淋病診断薬市場：地域別 2021-2031
    • 中東・アフリカ
      • GCC
      • アフリカ
      • その他中東・アフリカ地域

第11章 企業プロファイル

  • Abbott Laboratories
  • Agilent Technologies
  • Beckman Coulter Inc.
  • Becton Dickinson & Company
  • bioMerieux Inc.
  • Cepheid Inc.
  • F. Hoffmann-La Roche AG
  • Ortho Clinical Diagnostics
  • PerkinElmer Inc.
  • Pfizer Inc.
  • Roche Diagnostics
  • Siemens AG
  • Tosoh Corporation
  • Others notable players
図表

List of Tables

  • TABLE 1 Global Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 2 Global Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 3 North America Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 4 North America Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 5 U.S. Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 6 U.S. Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 7 Canada Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 8 Canada Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 9 Rest of North America Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 10 Rest of North America Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 11 UK and European Union Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 12 UK and European Union Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 13 UK Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 14 UK Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 15 Germany Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 16 Germany Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 17 Spain Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 18 Spain Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 19 Italy Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 20 Italy Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 21 France Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 22 France Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 23 Rest of Europe Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 24 Rest of Europe Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 25 Asia Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 26 Asia Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 27 China Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 28 China Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 29 Japan Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 30 Japan Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 31 India Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 32 India Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 33 Australia Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 34 Australia Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 35 South Korea Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 36 South Korea Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 37 Latin America Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 38 Latin America Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 39 Brazil Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 40 Brazil Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 41 Mexico Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 42 Mexico Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 43 Rest of Latin America Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 44 Rest of Latin America Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 45 Middle East and Africa Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 46 Middle East and Africa Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 47 GCC Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 48 GCC Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 49 Africa Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 50 Africa Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Gonorrhea Diagnostics Market By Type, 2021-2031, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Gonorrhea Diagnostics Market By Molecular Diagnostic Tests, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Gonorrhea Diagnostics Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Gonorrhea Diagnostics Market: Quality Assurance
  • FIG. 5 Global Gonorrhea Diagnostics Market, By Type, 2022
  • FIG. 6 Global Gonorrhea Diagnostics Market, By Geography, 2022
  • FIG. 7 Market Geographical Opportunity Matrix - Global Gonorrhea Diagnostics Market, 2022
  • FIG. 8 Market Positioning of Key Gonorrhea Diagnostics Market Players, 2022
  • FIG. 9 Global Gonorrhea Diagnostics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
  • FIG. 10 Global Gonorrhea Diagnostics Market, By Type, 2022 Vs 2031, %
  • FIG. 11 U.S. Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 12 Canada Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 13 Rest of North America Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 14 UK Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 15 Germany Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 16 Spain Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 17 Italy Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 18 France Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 19 Rest of Europe Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 20 China Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 21 Japan Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 22 India Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 23 Australia Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 24 South Korea Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 25 Rest of Asia Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 26 Brazil Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 27 Mexico Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 28 Rest of Latin America Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 29 GCC Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 30 Africa Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
  • FIG. 31 Rest of Middle East and Africa Gonorrhea Diagnostics Market (US$ Million), 2021 - 2031
目次
Product Code: 137976-01-23

Gonorrhea is caused due to the infection of bacterium Neisseria gonorrhea which usually affects the moist and warm areas of the body such as vagina, anus, urethra, throat and eyes. It is classified as the second most occurring sexually transmitted disease (STD) as it has the risk to spread through unprotected sex or having multiple sex partners. Due to high morbidity rate and eminent threat of gonorrhea being resistant to cephalosporin, makes it necessary to understand the disease epidemiology of gonorrhea. As per the latest research citing of the Centers for Disease Control and Prevention's 2016 report, the global prevalence of gonorrhea is 142.1 cases per 100,000 people. The occurrence is high in women in comparison to men and widely prevalent in regions such as North America, Latin America, Africa and other developing nations of South Asia.

The World Health Organization has postulated a treatment guideline for gonorrhea in order to overcome problem of microbial resistance, which consists of use of antibiotics such as third generation cephalosporins, doxycycline, azithromycin, gemifloxacin etc. For effective diagnosis of gonorrhea, cell culture standard test is considered as gold standard due to inherent features such as high specificity, high sensitivity and relatively low cost. The problems associated with cell culture of Neisseria is the need to maintain the bacterial viability during storage and transport, and approximately 24-72 hours are required before a preliminary culture test result is obtained. Nucleic acid amplification test (NAAT) has been approved by the USFDA for analyzing genital specimen only, and has been beneficial to gain positive results with very less genetic material, urine samples and vaginal swabs. For analyzing extra genital specimen, gonorrhea diagnosis is performed with serological tests, monoclonal antibodies tests, and flow cytometry etc.

Key players identified for gonorrhea diagnostics market includes:

Abbott Laboratories, Agilent Technologies, Beckman Coulter, Inc., Becton Dickinson & Company, bioMerieux, Inc., Cepheid, Inc., F. Hoffmann-La Roche AG, Ortho Clinical Diagnostics, PerkinElmer, Inc., Pfizer, Inc., Roche Diagnostics, Siemens AG, Tosoh Corporation and Others notable players.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Gonorrhea Diagnostics market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Gonorrhea Diagnostics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

Flow Cytometry

Diagnostic Imaging

Gel Microdroplets

Chromatography

Liposomes

Monoclonal Antibodies Tests

Differential Light Scattering

Molecular Diagnostic Tests

Swab Tests

Nucleic Acid Amplification Tests (NAAT)

Region Segment (2021-2031; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Gonorrhea Diagnostics market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2031.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Gonorrhea Diagnostics market?

Which is the largest regional market for Gonorrhea Diagnostics market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Gonorrhea Diagnostics market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Gonorrhea Diagnostics market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Gonorrhea Diagnostics Market
  • 2.2. Global Gonorrhea Diagnostics Market, By Type, 2022 (US$ Million)
  • 2.3. Global Gonorrhea Diagnostics Market, By Geography, 2022 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2022

3. Gonorrhea Diagnostics Market: Competitive Analysis

  • 3.1. Market Positioning of Key Gonorrhea Diagnostics Market Vendors
  • 3.2. Strategies Adopted by Gonorrhea Diagnostics Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Gonorrhea Diagnostics Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Gonorrhea Diagnostics Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Flow Cytometry
    • 5.3.2. Diagnostic Imaging
    • 5.3.3. Gel Microdroplets
    • 5.3.4. Chromatography
    • 5.3.5. Liposomes
    • 5.3.6. Monoclonal Antibodies Tests
    • 5.3.7. Differential Light Scattering
    • 5.3.8. Molecular Diagnostic Tests
      • 5.3.8.1. Swab Tests
      • 5.3.8.2. Nucleic Acid Amplification Tests (NAAT)

6. North America Gonorrhea Diagnostics Market, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
  • 6.3.Gonorrhea Diagnostics Market: By Region, 2021-2031, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)

7. UK and European Union Gonorrhea Diagnostics Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
  • 7.3.Gonorrhea Diagnostics Market: By Region, 2021-2031, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)

8. Asia Pacific Gonorrhea Diagnostics Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
  • 8.3.Gonorrhea Diagnostics Market: By Region, 2021-2031, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)

9. Latin America Gonorrhea Diagnostics Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
  • 9.3.Gonorrhea Diagnostics Market: By Region, 2021-2031, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)

10. Middle East and Africa Gonorrhea Diagnostics Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
  • 10.3.Gonorrhea Diagnostics Market: By Region, 2021-2031, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Gonorrhea Diagnostics Market: By Type, 2021-2031, USD (Million)

11. Company Profile

  • 11.1. Abbott Laboratories
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Agilent Technologies
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Beckman Coulter, Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Becton Dickinson & Company
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. bioMerieux, Inc.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Cepheid, Inc.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. F. Hoffmann-La Roche AG
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Ortho Clinical Diagnostics
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. PerkinElmer, Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Pfizer, Inc.
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives
  • 11.11. Roche Diagnostics
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Portfolio
    • 11.11.4. Strategic Initiatives
  • 11.12. Siemens AG
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Portfolio
    • 11.12.4. Strategic Initiatives
  • 11.13. Tosoh Corporation
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Portfolio
    • 11.13.4. Strategic Initiatives
  • 11.14. Others notable players
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Portfolio
    • 11.14.4. Strategic Initiatives